ViiV to begin trials of HIV prevention injection

06:38 EST 1 Dec 2016 | pharmaphorum

GlaxoSmithKline’s ViiV Healthcare joint venture is developing an injectable pre-exposure prophylaxis (PrEP) which can prevent permanent HIV infection According to Reuters, ViiV, a joint venture between GSK, Pfizer and Shionogi, is developing the ...

Original Article: ViiV to begin trials of HIV prevention injection


More From BioPortfolio on "ViiV to begin trials of HIV prevention injection"

Quick Search

Relevant Topics

GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...